Novavax is a biotechnology company based in Gaithersburg, Maryland, focused on developing recombinant vaccines, including its COVID-19 vaccines Nuvaxovid and other candidates. The company employs 1,543 people and utilizes advanced nanoparticle technology and its Matrix-M adjuvant to enhance immune responses.
NVAX has been in the news recently: Vinay Prasad has been appointed as the new director of the FDA's Center of Biologics Evaluation and Research. Novavax Inc. reported first-quarter 2025 sales of $667 million, significantly exceeding last year's $94 million and surpassing analysts' expectations.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
